
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5611884/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The global threat of antimicrobial resistance: science for intervention. New Microbes and New Infections, 2015, 6, 22-29.	1.6	811
2	Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. Journal of Antimicrobial Chemotherapy, 2006, 58, 256-265.	3.0	640
3	EUCAST expert rules in antimicrobial susceptibility testing. Clinical Microbiology and Infection, 2013, 19, 141-160.	6.0	527
4	The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. Clinical Microbiology and Infection, 2017, 23, 2-22.	6.0	428
5	A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. Journal of Antimicrobial Chemotherapy, 2001, 47, 399-403.	3.0	361
6	European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. Journal of Antimicrobial Chemotherapy, 2003, 52, 145-148.	3.0	323
7	Evaluation of Current Methods for Detection of Staphylococci with Reduced Susceptibility to Glycopeptides. Journal of Clinical Microbiology, 2001, 39, 2439-2444.	3.9	290
8	The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clinical Microbiology and Infection, 2012, 18, E37-E45.	6.0	232
9	Antibiotic treatment of Gram-positive bone and joint infections. Journal of Antimicrobial Chemotherapy, 2004, 53, 928-935.	3.0	221
10	European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing. Clinical Microbiology and Infection, 2006, 12, 501-503.	6.0	176
11	Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resistance Updates, 2011, 14, 107-117.	14.4	175
12	Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. Journal of Antimicrobial Chemotherapy, 2002, 50, 73-77.	3.0	169
13	Establishing MIC breakpoints and the interpretation of <i>in vitro</i> susceptibility tests. Journal of Antimicrobial Chemotherapy, 2001, 48, 17-28.	3.0	166
14	Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. Journal of Antimicrobial Chemotherapy, 2004, 53, 1018-1032.	3.0	126
15	Vancomycin-resistant Staphylococcus aureus. Lancet, The, 1998, 351, 602.	13.7	121
16	A Multicenter Study Evaluating the Current Strategies for Isolating Staphylococcus aureus Strains with Reduced Susceptibility to Glycopeptides. Journal of Clinical Microbiology, 2007, 45, 329-332.	3.9	120
17	Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. Journal of Antimicrobial Chemotherapy, 2000, 45, 835-841.	3.0	119
18	The occurrence and seasonal changes in the isolation of Listeria spp. in shop bought food stuffs, human faeces, sewage and soil from urban sources. International Journal of Food Microbiology, 1994, 21, 325-334.	4.7	118

#	Article	IF	CITATIONS
19	Sequence analysis and enzyme kinetics of the L2 serine beta-lactamase from Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy, 1997, 41, 1460-1464.	3.2	109
20	Genetic basis of tetracycline resistance in clinical isolates of Listeria monocytogenes. Antimicrobial Agents and Chemotherapy, 1992, 36, 463-466.	3.2	106
21	Pharmacodynamics, Pharmacokinetics, and Therapeutic Drug Monitoring of Glycopeptides. Therapeutic Drug Monitoring, 1998, 20, 473-477.	2.0	106
22	Clothing in laminar-flow operating theatres. Journal of Hospital Infection, 1996, 32, 1-7.	2.9	104
23	Importance of air quality and related factors in the prevention of infection in orthopaedic implant surgery. Journal of Hospital Infection, 1998, 39, 173-180.	2.9	104
24	The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public–private partnerships for the development of new strategies to tackle antibiotic resistance. Journal of Antimicrobial Chemotherapy, 2016, 71, 290-295.	3.0	101
25	A controlled trial of selective decontamination of the digestive tract in intensive care and its effect on nosocomial infection. Journal of Antimicrobial Chemotherapy, 1992, 30, 73-87.	3.0	97
26	Microneedle biosensors for real-time, minimally invasive drug monitoring of phenoxymethylpenicillin: a first-in-human evaluation in healthy volunteers. The Lancet Digital Health, 2019, 1, e335-e343.	12.3	96
27	Letters to the Editor. Journal of Hospital Infection, 1999, 43, 69-70.	2.9	95
28	Continuous Infusion of ??-Lactam Antibiotics. Clinical Pharmacokinetics, 1998, 35, 391-402.	3.5	91
29	Listeria monocytogenes and its role in human infection. Journal of Infection, 1988, 17, 7-28.	3.3	85
30	Tigecycline pharmacokinetic/pharmacodynamic update. Journal of Antimicrobial Chemotherapy, 2008, 62, i11-i16.	3.0	80
31	Distribution and expression of beta-lactamase genes among Aeromonas spp. Journal of Antimicrobial Chemotherapy, 1997, 40, 171-178.	3.0	75
32	Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. Journal of Antimicrobial Chemotherapy, 2005, 55, 333-340.	3.0	74
33	A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum. Journal of Antimicrobial Chemotherapy, 2001, 48, 605-608.	3.0	73
34	Activities of Moxifloxacin against, and Emergence of Resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an In Vitro Pharmacokinetic Model. Antimicrobial Agents and Chemotherapy, 2003, 47, 1088-1095.	3.2	72
35	EUCAST Technical Note on tigecycline. Clinical Microbiology and Infection, 2006, 12, 1147-1149.	6.0	72
36	One- and two-stage surgical revision of peri-prosthetic joint infection of the hip: a pooled individual participant data analysis of 44 cohort studies. European Journal of Epidemiology, 2018, 33, 933-946.	5.7	69

#	Article	IF	CITATIONS
37	Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. Journal of Antimicrobial Chemotherapy, 2002, 50, 713-718.	3.0	67
38	Clinical implications of antimicrobial resistance for therapy. Journal of Antimicrobial Chemotherapy, 2008, 62, ii105-ii114.	3.0	67
39	One-stage or two-stage revision surgery for prosthetic hip joint infection – the INFORM trial: a study protocol for a randomised controlled trial. Trials, 2016, 17, 90.	1.6	66
40	A clinical isolate of Aeromonas sobria with three chromosomally mediated inducible β-lactamases: a cephalosporinase, a penicillinase and a third enzyme, displaying carbapenemase activity. Journal of Antimicrobial Chemotherapy, 1995, 35, 271-279.	3.0	63
41	Enzyme kinetics and biochemical analysis of ImiS, the metallo-β-lactamase from Aeromonas sobria 163a. Journal of Antimicrobial Chemotherapy, 1996, 37, 423-431.	3.0	61
42	Comparative Bactericidal Activities of Daptomycin and Vancomycin against Glycopeptide-Intermediate Staphylococcus aureus (GISA) and Heterogeneous GISA Isolates. Antimicrobial Agents and Chemotherapy, 2006, 50, 4195-4197.	3.2	61
43	Does laboratory antibiotic susceptibility reporting influence primary care prescribing in urinary tract infection and other infections?. Journal of Antimicrobial Chemotherapy, 2011, 66, 1396-1404.	3.0	61
44	A review of the pharmacokinetics and pharmacodynamics of aztreonam. Journal of Antimicrobial Chemotherapy, 2016, 71, 2704-2712.	3.0	61
45	The relationship between primary care antibiotic prescribing and bacterial resistance in adults in the community: a controlled observational study using individual patient data. Journal of Antimicrobial Chemotherapy, 2005, 56, 146-153.	3.0	60
46	A review of the clinical presentation, laboratory features, antimicrobial therapy and outcome of 77 episodes of pneumococcal meningitis occurring in children and adults. Journal of Infection, 1994, 29, 171-182.	3.3	58
47	A systematic review of matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry compared to routine microbiological methods for the time taken to identify microbial organisms from positive blood cultures. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 863-876.	2.9	57
48	The Diagnosis of Urinary Tract infection in Young children (DUTY): a diagnostic prospective observational study to derive and validate a clinical algorithm for the diagnosis of urinary tract infection in children presenting to primary care with an acute illness. Health Technology Assessment, 2016, 20, 1-294.	2.8	56
49	Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1. Antimicrobial Agents and Chemotherapy, 2016, 60, 1183-1193.	3.2	55
50	Typing of Listeria spp. by random amplified polymorphic DNA (RAPD) analysis. Journal of Medical Microbiology, 1993, 38, 322-327.	1.8	54
51	Listeria faecal carriage by renal transplant recipients, haemodialysis patients and patients in general practice: its relation to season, drug therapy, foreign travel, animal exposure and diet. Epidemiology and Infection, 1991, 106, 157-166.	2.1	53
52	Expression of lux Genes in a Clinical Isolate of Streptococcus pneumoniae : Using Bioluminescence To Monitor Gemifloxacin Activity. Antimicrobial Agents and Chemotherapy, 2002, 46, 538-542.	3.2	53
53	Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review. Journal of Antimicrobial Chemotherapy, 2016, 71, 2754-2759.	3.0	53
54	The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosaassessed by combining antibiotic exposure and bacterial susceptibility. Journal of Antimicrobial Chemotherapy, 1999, 43, 345-349.	3.0	52

#	Article	IF	CITATIONS
55	Surveillance of antimicrobial resistance. BMJ: British Medical Journal, 1998, 317, 614-615.	2.3	51
56	Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models. International Journal of Antimicrobial Agents, 2002, 19, 291-298.	2.5	51
57	Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service. Journal of Antimicrobial Chemotherapy, 2010, 65, 2155-2157.	3.0	49
58	Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18. Journal of Antimicrobial Chemotherapy, 2020, 75, 65-71.	3.0	49
59	Sequence analysis of two chromosomally mediated inducible β-lactamases from Aeromonas sobria, strain 163a, one a class D penicillinase, the other an AmpC cephalosporinase. Journal of Antimicrobial Chemotherapy, 1995, 36, 41-52.	3.0	48
60	The Excess Cost of Acute Exacerbations of Chronic Bronchitis in Patients Aged 45 and Older in England and Wales. Value in Health, 2001, 4, 370-375.	0.3	48
61	Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria. Journal of Antimicrobial Chemotherapy, 1997, 40, 503-509.	3.0	47
62	Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 1999, 44, 675-678.	3.0	47
63	The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens. Journal of Antimicrobial Chemotherapy, 2000, 46, 163-170.	3.0	47
64	NDM-1 polymicrobial infections including Vibrio cholerae. Lancet, The, 2012, 380, 1358.	13.7	47
65	Pharmacodynamics of Ceftaroline against Staphylococcus aureus Studied in an <i>In Vitro</i> Pharmacokinetic Model of Infection. Antimicrobial Agents and Chemotherapy, 2013, 57, 2451-2456.	3.2	47
66	Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper. Clinical Microbiology and Infection, 2020, 26, 1039-1043.	6.0	47
67	Revisiting Beta-lactams – PK/PD improves dosing of old antibiotics. Current Opinion in Pharmacology, 2011, 11, 470-476.	3.5	46
68	Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. Expert Opinion on Investigational Drugs, 1999, 8, 181-199.	4.1	45
69	The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments. International Journal of Antimicrobial Agents, 2015, 46, 560-567.	2.5	45
70	Human peritoneal macrophage phagocytic, killing, and chemiluminescent responses to opsonized Listeria monocytogenes. Infection and Immunity, 1983, 40, 440-443.	2.2	45
71	In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and β-haemolytic streptococci. Journal of Antimicrobial Chemotherapy, 1999, 44, 445-453.	3.0	44
72	Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory. International Journal of Antimicrobial Agents, 2006, 28, 574-577.	2.5	44

#	Article	IF	CITATIONS
73	Evolution of mobile genetic element composition in an epidemic methicillin-resistant Staphylococcus aureus: temporal changes correlated with frequent loss and gain events. BMC Genomics, 2017, 18, 684.	2.8	43
74	Endophthalmitis at the Bristol Eye Hospital: an 11-year review of 47 patients. Journal of Hospital Infection, 1992, 22, 271-278.	2.9	42
75	An HPLC assay for daptomycin in serum. Journal of Antimicrobial Chemotherapy, 2008, 62, 1462-1463.	3.0	42
76	Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2. Antimicrobial Agents and Chemotherapy, 2016, 60, 1194-1201.	3.2	42
77	Predicting outcomes of COVID-19 from admission biomarkers: a prospective UK cohort study. Emergency Medicine Journal, 2021, 38, 543-548.	1.0	42
78	Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy. Journal of Antimicrobial Chemotherapy, 1993, 32, 117-122.	3.0	41
79	Salt tolerance of EMRSA-16 and its effect on the sensitivity of screening cultures. Journal of Hospital Infection, 1997, 35, 59-62.	2.9	41
80	Bactericidal Activity of Multiple Combinations of Tigecycline and Colistin against NDM-1-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2012, 56, 3441-3443.	3.2	41
81	Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy. Journal of Antimicrobial Chemotherapy, 1990, 25, 837-842.	3.0	40
82	Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society of Antimicrobial Chemotherapy breakpoints. Journal of Antimicrobial Chemotherapy, 1998, 42, 161-169.	3.0	40
83	Risk Factors for Treatment Failure and Mortality among Hospitalised Patients with Complicated Urinary Tract Infection: A Multicentre Retrospective Cohort Study, RESCUING Study Group. Clinical Infectious Diseases, 2018, 68, 29-36.	5.8	40
84	Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. Journal of Antimicrobial Chemotherapy, 2006, 58, 802-805.	3.0	38
85	Role of early intravenous to oral antibiotic switch therapy in the management of prosthetic hip infection treated with one- or two-stage replacement. Journal of Antimicrobial Chemotherapy, 2011, 66, 2405-2408.	3.0	38
86	Colistin susceptibility testing: time for a review. Journal of Antimicrobial Chemotherapy, 2014, 69, 1432-1434.	3.0	38
87	Activity of Moxifloxacin, Administered Once a Day, against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model of Infection. Antimicrobial Agents and Chemotherapy, 1999, 43, 1560-1564.	3.2	38
88	Virulence of Listeria spp.: Course of infection in resistant and susceptible mice. Journal of Medical Microbiology, 1988, 27, 131-140.	1.8	36
89	The use and therapeutic drug monitoring of teicoplanin in the UK. Clinical Microbiology and Infection, 2004, 10, 62-69.	6.0	36
90	Reduced expression of the atl autolysin gene and susceptibility to autolysis in clinical heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA) and GISA strains. Journal of Antimicrobial Chemotherapy, 2005, 56, 944-947.	3.0	36

#	Article	IF	CITATIONS
91	Widespread implementation of EUCAST breakpoints for antibacterial susceptibility testing in Europe. Eurosurveillance, 2015, 20, .	7.0	36
92	The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra- abdominal disease. Journal of Antimicrobial Chemotherapy, 1997, 40, 121-124.	3.0	35
93	Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography. Journal of Antimicrobial Chemotherapy, 2001, 47, 271-275.	3.0	35
94	Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and Â-haemolytic streptococci collected from western European countries in 2011. Journal of Antimicrobial Chemotherapy, 2013, 68, 164-167.	3.0	35
95	Ciprofloxacin resistant Serratia marcescens endocarditis as a complication of non-Hodgkin's lymphoma. Journal of Infection, 1994, 29, 73-76.	3.3	34
96	The pharmacokinetics of meropenem in surgical patients with moderate or severe infections. Journal of Antimicrobial Chemotherapy, 1995, 36, 165-172.	3.0	34
97	Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. Antimicrobial Agents and Chemotherapy, 1996, 40, 2167-2172.	3.2	34
98	Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections. Antimicrobial Resistance and Infection Control, 2018, 7, 111.	4.1	34
99	Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study. BMJ Open, 2018, 8, e020251.	1.9	34
100	A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative β-lactam, aminoglycoside and fluoroquinolone. Journal of Antimicrobial Chemotherapy, 1996, 38, 193-203.	3.0	33
101	Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study. International Journal of Antimicrobial Agents, 2020, 55, 105847.	2.5	33
102	Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome. Journal of Infection and Chemotherapy, 1996, 2, 197-208.	1.7	32
103	In Vitro Models, In Vivo Models, and Pharmacokinetics: What Can We Learn from In Vitro Models?. Clinical Infectious Diseases, 2001, 33, S214-S220.	5.8	32
104	Clinical outcomes of hospitalised patients with catheter-associated urinary tract infection in countries with a high rate of multidrug-resistance: the COMBACTE-MAGNET RESCUING study. Antimicrobial Resistance and Infection Control, 2019, 8, 198.	4.1	32
105	An eight-year survey of the antimicrobial susceptibility patterns of 85,971 bacteria isolated from patients in a district general hospital and the local community. Journal of Antimicrobial Chemotherapy, 1993, 31, 543-557.	3.0	31
106	Hospital-acquired Clostridium difficile diarrhoea. Lancet, The, 1997, 349, 1176-1177.	13.7	31
107	Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia. International Journal of Antimicrobial Agents, 2017, 49, 98-101.	2.5	31
108	Health care resource utilization and antimicrobial use in elderly patients with community-acquired lower respiratory tract infection who develop Clostridium difficile-associated diarrhoea. Journal of Antimicrobial Chemotherapy, 1997, 39, 537-541.	3.0	30

#	Article	IF	CITATIONS
109	Elements of design: the knowledge on which we build. Clinical Microbiology and Infection, 2004, 10, 6-11.	6.0	30
110	Eucast Technical Note on daptomycin. Clinical Microbiology and Infection, 2006, 12, 599-601.	6.0	30
111	Antimicrobial resistance surveillance in urinary tract infections in primary care: TableÂ1 Journal of Antimicrobial Chemotherapy, 2016, 71, 2723-2728.	3.0	30
112	Interactions between Methicillin and Vancomycin in Methicillin-Resistant Staphylococcus aureus Strains Displaying Different Phenotypes of Vancomycin Susceptibility. Journal of Clinical Microbiology, 1999, 37, 3068-3071.	3.9	30
113	Use of a clinical Escherichia coli isolate expressing lux genes to study the antimicrobial pharmacodynamics of moxifloxacin. Journal of Antimicrobial Chemotherapy, 1999, 43, 829-832.	3.0	29
114	Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: the BSAC Respiratory Resistance Surveillance Programme. Journal of Antimicrobial Chemotherapy, 2003, 52, 925-930.	3.0	29
115	Evidence for Reduction in Breakpoints Used To Determine Vancomycin Susceptibility in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2005, 49, 3982-3983.	3.2	29
116	Pharmacodynamics of Telavancin Studied in an <i>In Vitro</i> Pharmacokinetic Model of Infection. Antimicrobial Agents and Chemotherapy, 2011, 55, 867-873.	3.2	29
117	Improving the Diagnosis and Treatment of Urinary Tract Infection in Young Children in Primary Care: Results from the DUTY Prospective Diagnostic Cohort Study. Annals of Family Medicine, 2016, 14, 325-336.	1.9	29
118	Supplementary report by the Working Party on antibiotic sensitivity testing of the British Society for Antimicrobial Chemotherapy, 1996, 38, 1103-1105.	3.0	28
119	The penetration of ceftriaxone and cefamandole into bone, fat and haematoma and relevance of serum protein binding to their penetration into bone. Journal of Antimicrobial Chemotherapy, 2001, 47, 483-486.	3.0	28
120	BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials. Journal of Antimicrobial Chemotherapy, 2002, 49, 535-539.	3.0	28
121	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. Clinical Pharmacokinetics, 2020, 59, 1195-1216.	3.5	28
122	Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin. Journal of Antimicrobial Chemotherapy, 1999, 44, 661-667.	3.0	27
123	Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07. Journal of Antimicrobial Chemotherapy, 2012, 67, 2912-2918.	3.0	27
124	Risk factors and prognosis of complicated urinary tract infections caused by Pseudomonas aeruginosa in hospitalized patients: a retrospective multicenter cohort study. Infection and Drug Resistance, 2018, Volume 11, 2571-2581.	2.7	27
125	Maternal listeriosis in pregnancy without fetal or neonatal infection. Journal of Infection, 1991, 22, 53-57.	3.3	26
126	Pharmacodynamics of Minocycline against <i>Staphylococcus aureus</i> in an In Vitro Pharmacokinetic Model. Antimicrobial Agents and Chemotherapy, 2008, 52, 4370-4373.	3.2	26

#	Article	IF	CITATIONS
127	The diagnosis of urinary tract infections in young children (DUTY): protocol for a diagnostic and prospective observational study to derive and validate a clinical algorithm for the diagnosis of UTI in children presenting to primary care with an acute illness. BMC Infectious Diseases, 2012, 12, 158.	2.9	26
128	Factors influencing the clinical outcome of methicillin-resistant Staphylococcus aureus bacteraemia. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 295-301.	2.9	26
129	The use of intravesical gentamicin to treat recurrent urinary tract infections in lower urinary tract dysfunction. Neurourology and Urodynamics, 2017, 36, 2109-2116.	1.5	26
130	Typing of Listeria monocytogenes by random amplified polymorphic DNA (RAPD) analysis. International Journal of Food Microbiology, 1995, 27, 245-252.	4.7	24
131	Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study. Clinical Infectious Diseases, 2020, 70, 2270-2280.	5.8	24
132	A 10 year survey of the epidemiology and clinical aspects of listeriosis in a provincial English city. Journal of Infection, 1994, 29, 91-103.	3.3	23
133	Bactericidal activity, post antibiotic effect and modified controlled effective regrowth time of meropenem at high concentrations. Journal of Antimicrobial Chemotherapy, 1996, 38, 1055-1060.	3.0	23
134	Heterogeneous resistance to vancomycin in Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 2000, 45, 130-131.	3.0	23
135	A reverse-phase HPLC assay for the simultaneous determination of enrofloxacin and ciprofloxacin in pig faeces. International Journal of Antimicrobial Agents, 2004, 23, 390-393.	2.5	23
136	Pharmacodynamics of the Antibacterial Effect and Emergence of Resistance to Tomopenem, Formerly RO4908463/CS-023, in an In Vitro Pharmacokinetic Model of <i>Staphylococcus aureus</i> Infection. Antimicrobial Agents and Chemotherapy, 2008, 52, 1401-1406.	3.2	23
137	Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net. Clinical Infectious Diseases, 2018, 67, 1922-1931.	5.8	23
138	Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and streptococci of Lancefield Groups A and G. Journal of Antimicrobial Chemotherapy, 1999, 44, 761-766.	3.0	22
139	Pharmacodynamics of Gemifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model of Infection. Antimicrobial Agents and Chemotherapy, 2001, 45, 2916-2921.	3.2	22
140	Cefuroxime resistance in non-beta-lactamase Haemophilus influenzae is linked to mutations in ftsl. Journal of Antimicrobial Chemotherapy, 2003, 51, 523-530.	3.0	22
141	Development of a novel assay method for colistin sulphomethate. Clinical Microbiology and Infection, 2005, 11, 243-244.	6.0	22
142	Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia. Therapeutics and Clinical Risk Management, 2015, 11, 565.	2.0	22
143	Pharmacokinetics and tolerance of a new film-coated tablet of sodium fusidate administered as a single oral dose to healthy volunteers. Journal of Antimicrobial Chemotherapy, 1989, 23, 409-415.	3.0	21
144	In-vitro synergy testing of nine antimicrobial combinations against Listeria monocytogenes. Journal of Antimicrobial Chemotherapy, 1990, 25, 561-566.	3.0	21

#	Article	IF	CITATIONS
145	Pharmacokinetics of once-a-day netilmicin (6 mg/kg) in neonates. Journal of Antimicrobial Chemotherapy, 1996, 38, 499-505.	3.0	21
146	Role of Pharmacokinetics and Pharmacodynamics: Does the Dose Matter?. Clinical Infectious Diseases, 2001, 33, S238-S239.	5.8	21
147	Activity of AZD2563, a Novel Oxazolidinone, against Staphylococcus aureus Strains with Reduced Susceptibility to Vancomycin or Linezolid. Antimicrobial Agents and Chemotherapy, 2003, 47, 3651-3652.	3.2	21
148	Resistance determinants in strains of Clostridium difficile from two geographically distinct populations. International Journal of Antimicrobial Agents, 2004, 24, 619-621.	2.5	21
149	Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection. International Journal of Antimicrobial Agents, 2017, 50, 715-717.	2.5	21
150	Extent, quality and impact of patient and public involvement in antimicrobial drug development research: A systematic review. Health Expectations, 2018, 21, 75-81.	2.6	21
151	A simple high performance liquid chromatography (HPLC) assay for aciclovir and ganciclovir in serum. Journal of Antimicrobial Chemotherapy, 1996, 38, 739-740.	3.0	20
152	The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria. Journal of Antimicrobial Chemotherapy, 1996, 38, 271-281.	3.0	20
153	A comparison of the penetration of cefuroxime and cephamandole into bone, fat and haematoma fluid in patients undergoing total hip replacement. Journal of Antimicrobial Chemotherapy, 1997, 40, 99-104.	3.0	20
154	Back to basics in management of Clostridium difficile infections. Lancet, The, 1998, 352, 505-506.	13.7	20
155	Pharmacodynamics of Moxifloxacin against Anaerobes Studied in an In Vitro Pharmacokinetic Model. Antimicrobial Agents and Chemotherapy, 2005, 49, 4234-4239.	3.2	20
156	Breakpoints for extended-spectrum β-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations. Clinical Microbiology and Infection, 2008, 14, 166-168.	6.0	20
157	Serum ciprofloxacin concentrations in patients with severe sepsis being treated with ciprofloxacin 200 mg iv bd irrespective of renal function. Journal of Antimicrobial Chemotherapy, 1994, 33, 1051-1054.	3.0	19
158	Assay of low trough serum gentamicin concentrations by fluorescence polarization immunoassay. Journal of Antimicrobial Chemotherapy, 1994, 33, 1068-1070.	3.0	19
159	Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin. Journal of Antimicrobial Chemotherapy, 2000, 46, 73-78.	3.0	19
160	Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection. Journal of Antimicrobial Chemotherapy, 2009, 64, 1044-1051.	3.0	19
161	Pharmacodynamics of Razupenem (PZ601) Studied in anIn VitroPharmacokinetic Model of Infection. Antimicrobial Agents and Chemotherapy, 2011, 55, 1436-1442.	3.2	19
162	Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum. Journal of Antimicrobial Chemotherapy, 2013, 68, 1130-1138.	3.0	19

#	Article	IF	CITATIONS
163	Methodological features of clinical pharmacokinetic–pharmacodynamic studies of antibacterials and antifungals: a systematic review. Journal of Antimicrobial Chemotherapy, 2020, 75, 1374-1389.	3.0	19
164	Combination versus monotherapy as definitive treatment for <i>Pseudomonas aeruginosa</i> bacteraemia: a multicentre retrospective observational cohort study. Journal of Antimicrobial Chemotherapy, 2021, 76, 2172-2181.	3.0	19
165	Heterogeneity at the Â-lactamase structural gene ampC amongst Citrobacter spp. assessed by polymerase chain reaction analysis: potential for typing at a molecular level. Journal of Medical Microbiology, 1994, 41, 209-214.	1.8	18
166	Detection of glycopeptide resistance in Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 2001, 47, 357-358.	3.0	18
167	In vitro activity of 21 antimicrobials against vancomycin-resistant Staphylococcus aureus (VRSA) and heteroVRSA (hVRSA). Journal of Antimicrobial Chemotherapy, 2002, 50, 760-761.	3.0	18
168	Antibacterial Effects of Amoxicillin-Clavulanate against Streptococcus pneumoniae and Haemophilus influenzae Strains for Which MICs Are High, in an In Vitro Pharmacokinetic Model. Antimicrobial Agents and Chemotherapy, 2004, 48, 2599-2603.	3.2	18
169	Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an <i>In Vitro</i> Pharmacokinetic Model of Infection. Antimicrobial Agents and Chemotherapy, 2016, 60, 515-521.	3.2	18
170	The pharmacokinetics of once daily gentamicin in neutropenic adults with haematological malignancy. Journal of Antimicrobial Chemotherapy, 1994, 34, 809-812.	3.0	17
171	For debate. Journal of Antimicrobial Chemotherapy, 1994, 34, 829-837.	3.0	17
172	Evaluation of Innofluor fluorescence polarization immunoassay kits for the determination of serum concentrations of gentamicin, tobramycin, amikacin and vancomycin.lesassays@ukneqasaa.win-uk.net. Journal of Antimicrobial Chemotherapy, 1997, 39, 355-361.	3.0	17
173	Comparative pharmacodynamics of meropenem using an in-vitro model to simulate once, twice and three times daily dosing in humans. Journal of Antimicrobial Chemotherapy, 1998, 42, 461-467.	3.0	17
174	Mechanism of Fluoroquinolone Resistance Is an Important Factor in Determining the Antimicrobial Effect of Gemifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model. Antimicrobial Agents and Chemotherapy, 2003, 47, 1096-1100.	3.2	17
175	Impact of rapid microbial identification on clinical outcomes in bloodstream infection: the RAPIDO randomized trial. Clinical Microbiology and Infection, 2020, 26, 1347-1354.	6.0	17
176	Listerious—the therapeutic options. Journal of Antimicrobial Chemotherapy, 1990, 26, 721-721.	3.0	16
177	Serum monitoring and practicalities of once-daily aminoglycoside dosing. Journal of Antimicrobial Chemotherapy, 1994, 33, 349-350.	3.0	16
178	The elution and binding characteristics of rifampicin for three commercially available protein-sealed vascular grafts. Journal of Antimicrobial Chemotherapy, 1996, 38, 599-604.	3.0	16
179	An isocratic high performance liquid chromatography (HPLC) assay for moxifloxacin, a new 8-methoxyquinolone. Journal of Antimicrobial Chemotherapy, 1998, 42, 278-279.	3.0	16
180	Antimicrobial susceptibility of lower respiratory tract pathogens in Great Britain and Ireland 1999-2001 related to demographic and geographical factors: the BSAC Respiratory Resistance Surveillance Programme. Journal of Antimicrobial Chemotherapy, 2003, 52, 931-943.	3.0	16

#	Article	IF	CITATIONS
181	Pharmacodynamics of linezolid in a clinical isolate of Streptococcus pneumoniae genetically modified to express lux genes. Journal of Antimicrobial Chemotherapy, 2003, 52, 511-513.	3.0	16
182	Pharmacodynamics of the Antibacterial Effect of and Emergence of Resistance to Doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an <i>In Vitro</i> Pharmacokinetic Model. Antimicrobial Agents and Chemotherapy, 2012, 56, 5009-5015.	3.2	16
183	Early warning score: a dynamic marker of severity and prognosis in patients with Gram-negative bacteraemia and sepsis. Annals of Clinical Microbiology and Antimicrobials, 2016, 15, 23.	3.8	16
184	An audit of the use of manual handling equipment and their microbiological flora —implications for infection control. Journal of Hospital Infection, 1999, 43, 309-313.	2.9	15
185	In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens. International Journal of Antimicrobial Agents, 2003, 22, 557-561.	2.5	15
186	Bacterial Strain-to-Strain Variation in Pharmacodynamic Index Magnitude, a Hitherto Unconsidered Factor in Establishing Antibiotic Clinical Breakpoints. Antimicrobial Agents and Chemotherapy, 2009, 53, 5181-5184.	3.2	15
187	Future treatment options for Gram-positive infections—looking ahead. Clinical Microbiology and Infection, 2009, 15, 17-25.	6.0	15
188	Kinetics and performance of the Abbott architect SARS-CoV-2 IgG antibody assay. Journal of Infection, 2020, 81, e7-e9.	3.3	15
189	The pharmacokinetics of norfloxacin in the aged. Journal of Antimicrobial Chemotherapy, 1988, 22, 721-727.	3.0	14
190	Relapsed infection due to Listeria monocytogenes confirmed by random amplified polymorphic DNA (RAPD) analysis. Journal of Infection, 1993, 27, 205-207.	3.3	14
191	Concentration controlled and concentration defined clinical trials: do they offer any advantages for antimicrobial chemotherapy?. Journal of Antimicrobial Chemotherapy, 1996, 37, 1-5.	3.0	14
192	External quality assessment of the serum bactericidal test: results of a methodology/interpretation questionnaire. Journal of Antimicrobial Chemotherapy, 1997, 39, 277-284.	3.0	14
193	Three cases of meningococcal pneumonia Thorax, 1997, 52, 927-929.	5.6	14
194	Surveillance of antimicrobial resistance. Lancet, The, 1998, 352, 1783.	13.7	14
195	Detection of extended-spectrum beta-lactamases with Etest and double-disc potentiation methods. Journal of Antimicrobial Chemotherapy, 2000, 46, 327-328.	3.0	14
196	Expression of tcaA and mprF and glycopeptide resistance in clinical glycopeptide-intermediate Staphylococcus aureus (CISA) and heteroCISA strains. Biochimica Et Biophysica Acta - General Subjects, 2005, 1726, 326-327.	2.4	14
197	The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β -lactamase-producing Enterobacteriaceae studied in an <i>in vitro</i> model of infection. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw480.	3.0	14
198	An <i>inÂvitro</i> biofilm model of <i>Staphylococcus aureus</i> infection of bone. Letters in Applied Microbiology, 2019, 68, 294-302.	2.2	14

#	Article	IF	CITATIONS
199	Needlestick injuries among medical students. Journal of Hospital Infection, 1993, 23, 315-317.	2.9	13
200	The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model. Journal of Antimicrobial Chemotherapy, 2001, 48, 727-730.	3.0	13
201	Determination by HPLC of chlortetracycline in pig faeces. Journal of Antimicrobial Chemotherapy, 2003, 52, 135-137.	3.0	13
202	Assay of ertapenem in human serum by high-performance liquid chromatography. International Journal of Antimicrobial Agents, 2006, 27, 165-167.	2.5	13
203	Prediction of Fluoroquinolone Susceptibility Directly from Whole-Genome Sequence Data by Using Liquid Chromatography-Tandem Mass Spectrometry To Identify Mutant Genotypes. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	13
204	Development, validation and application of a novel HPLC-MS/MS method for the measurement of minocycline in human plasma and urine. Journal of Pharmaceutical and Biomedical Analysis, 2019, 169, 90-98.	2.8	13
205	In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 2021, 76, 667-670.	3.0	13
206	Limited phylogenetic overlap between fluoroquinolone-resistant <i>Escherichia coli</i> isolated on dairy farms and those causing bacteriuria in humans living in the same geographical region. Journal of Antimicrobial Chemotherapy, 2021, 76, 3144-3150.	3.0	13
207	The comparative inhibitory and bactericidal activities of meropenem and imipenem against Acinetobacter spp. and Enterobacteriaceae resistant to second generation cephalosporins. Journal of Antimicrobial Chemotherapy, 1995, 35, 333-337.	3.0	12
208	Contamination of wounds by direct inoculation in total hip arthroplasty: a prospective clinical study. Journal of Hospital Infection, 1998, 40, 79-80.	2.9	12
209	A reverse-phase, isocratic high-performance liquid chromatography assay for levofloxacin. Journal of Antimicrobial Chemotherapy, 1999, 43, 434-435.	3.0	12
210	Ofloxacin Photodegradation Products Possess Antimicrobial Activity. Drugs, 1999, 58, 171-172.	10.9	12
211	A high performance liquid chromatography (HPLC) assay for linezolid in continuous ambulatory peritoneal dialysis fluid (CAPDF). Journal of Antimicrobial Chemotherapy, 2003, 51, 1041-1042.	3.0	12
212	Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection. Journal of Antimicrobial Chemotherapy, 2018, 73, 2411-2417.	3.0	12
213	A long history of \hat{I}^2 -lactams for MRSA. Nature Microbiology, 2019, 4, 1604-1605.	13.3	12
214	Challenges and opportunities for involving patients and the public in acute antimicrobial medicine development research: an interview study. BMJ Open, 2019, 9, e024918.	1.9	12
215	Pathways to optimising antibiotic use in rural China: identifying key determinants in community and clinical settings, a mixed methods study protocol. BMJ Open, 2019, 9, e027819.	1.9	12
216	HPLC assay of cefixime in serum and CSF. Journal of Antimicrobial Chemotherapy, 1993, 31, 450-450.	3.0	11

#	Article	IF	CITATIONS
217	Comparison of E test with conventional agar MICs for quinolones. Journal of Antimicrobial Chemotherapy, 1994, 33, 356-356.	3.0	11
218	A critical assessment of the agar dilution chequerboard technique for studying in-vitro antimicrobial interactions using a representative β-lactam, aminoglycoside and fluoroquinolone. Journal of Antimicrobial Chemotherapy, 1995, 35, 569-576.	3.0	11
219	Treatment of listeria meningitis. Lancet, The, 1997, 350, 1034.	13.7	11
220	Ampicillin-aminoglycoside interaction studies using Listeria monocytogenes. Journal of Antimicrobial Chemotherapy, 1998, 41, 417-418.	3.0	11
221	Pharmacokinetics of Once-a-Day Netilmicin (4.5 mg/kg) in Neonates. Journal of Chemotherapy, 2001, 13, 270-276.	1.5	11
222	Prevalence of antibiotic resistance in <i>Escherichia coli</i> isolated from urine samples routinely referred by general practitioners in a large urban centre in south-west England. Journal of Antimicrobial Chemotherapy, 2015, 70, 2167-2169.	3.0	11
223	Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance. Journal of Antimicrobial Chemotherapy, 2017, 72, 2704-2707.	3.0	11
224	Why monitor peak vancomycin concentrations?. Lancet, The, 1995, 345, 645-647.	13.7	10
225	Use of meropenem 3 g once daily for outpatient treatment of infective exacerbations of bronchiectasis. Journal of Antimicrobial Chemotherapy, 2000, 45, 247-250.	3.0	10
226	Viral infections in pregnancy: advice for healthcare workers. Journal of Hospital Infection, 2014, 87, 11-24.	2.9	10
227	Microbiology of acute bacterial skin and skin-structure infections in Greece: A proposed clinical prediction score for the causative pathogen. International Journal of Antimicrobial Agents, 2019, 54, 750-756.	2.5	10
228	Tricuspid valve infective endocarditis and pulmonary sepsis due to Erysipelothrix rhusiopathiae successfully treated with high doses of ciprofloxacin but complicated by gynaecomastia. Journal of Infection, 1991, 22, 100-101.	3.3	9
229	Venous allografts prepared from stripped long saphenous vein. Is there a need for antibiotic sterilisation?. European Journal of Vascular and Endovascular Surgery, 1998, 15, 444-448.	1.5	9
230	Epidemiology and resource utilization for patients hospitalized for lower respiratory tract infection. Clinical Microbiology and Infection, 2001, 7, 666-670.	6.0	9
231	EUCAST Technical Note on linezolid. Clinical Microbiology and Infection, 2006, 12, 1243-1245.	6.0	9
232	Occurrence and current frequency of CTX-M-type β-lactamases from a regional hospital in the South West of England. Journal of Antimicrobial Chemotherapy, 2007, 59, 815-816.	3.0	9
233	Harmonization of antimicrobial susceptibility testing breakpoints in Europe: implications for reporting intermediate susceptibility. Journal of Antimicrobial Chemotherapy, 2010, 65, 183-185.	3.0	9
234	Retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant Gram-negative bacteria (RESCUING). BMJ Open, 2016, 6, e011500.	1.9	9

#	Article	IF	CITATIONS
235	The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centres and the design of a disc test for susceptibility testing. Journal of Antimicrobial Chemotherapy, 1993, 32, 51-61.	3.0	8
236	The serum concentrations of desmethyl ofloxacin and ofloxacin N-oxide in seriously ill patients and their possible contributions to the antibacterial activity of ofloxacin. Journal of Antimicrobial Chemotherapy, 1994, 34, 300-303.	3.0	8
237	The quality of clinical serum teicoplanin assays: an experimental European EQA distribution. Journal of Antimicrobial Chemotherapy, 1996, 38, 701-706.	3.0	8
238	Sequential antimicrobial therapy: pharmacokinetic and pharmacodynamic considerations in sequential therapy. Journal of Infection, 1998, 37, 30-36.	3.3	8
239	A Comparative Study of the Rifampicin Binding and Elution Characteristics for Collagen- and Albumin-sealed Vascular Grafts. European Journal of Vascular and Endovascular Surgery, 1999, 17, 347-350.	1.5	8
240	In vitro activity of linezolid against Gram-positive isolates causing infection in continuous ambulatory peritoneal dialysis patients. Journal of Antimicrobial Chemotherapy, 2002, 49, 578-580.	3.0	8
241	Strain-Specific Expression Levels of pbp4 Exist in Isolates of Glycopeptide-Intermediate Staphylococcus aureus (GISA) and Heterogeneous GISA. Antimicrobial Agents and Chemotherapy, 2005, 49, 3598-3599.	3.2	8
242	Frontline antibiotic therapy. Clinical Medicine, 2013, 13, 263-268.	1.9	8
243	Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility. Clinical Microbiology and Infection, 2020, 26, 1692-1693.	6.0	8
244	The pharmacokinetics of lomefloxacin in elderly patients with urinary tract infection following daily dosing with 400 mg. Journal of Antimicrobial Chemotherapy, 1991, 28, 101-107.	3.0	7
245	Assay of serum teicoplanin concentrations in clinical specimens: a comparison of isocratic high performance liquid chromatography with polarisation fluoroimmunoassay and bioassay. Journal of Antimicrobial Chemotherapy, 1994, 34, 425-429.	3.0	6
246	In VitroStudies on the Impact of Human Serum on the Antibacterial Effect of Faropenem. Journal of Chemotherapy, 2004, 16, 23-29.	1.5	6
247	Genetic analysis of 17 genes in Staphylococcus aureus with reduced susceptibility to vancomycin (VISA) and heteroVISA. Journal of Antimicrobial Chemotherapy, 2004, 53, 406-407.	3.0	6
248	Problems of basing patient recruitment for primary care studies on routine laboratory submissions. Journal of Clinical Pathology, 2007, 60, 1290-1293.	2.0	6
249	Development, evaluation and application of an isocratic high-performance liquid chromatography (HPLC) assay for the simultaneous determination of aciclovir and its metabolite 9-carboxymethoxymethylguanine in human serum and cerebrospinal fluid. International Journal of Antimicrobial Agents. 2007, 30, 30-33.	2.5	6
250	In Vitro Activities of Three New Dihydrofolate Reductase Inhibitors against Clinical Isolates of Gram-Positive Bacteria. Antimicrobial Agents and Chemotherapy, 2009, 53, 4949-4952.	3.2	6
251	Nappy pad urine samples for investigation and treatment of UTI in young children: the â€ [~] DUTY' prospective diagnostic cohort study. British Journal of General Practice, 2016, 66, e516-e524.	1.4	6
252	Comparison of microbiological diagnosis of urinary tract infection in young children by routine health service laboratories and a research laboratory: Diagnostic cohort study. PLoS ONE, 2017, 12, e0171113.	2.5	6

#	Article	IF	CITATIONS
253	Finding and engaging patients and the public to work collaboratively on an acute infection microbiology research public panel. Research Involvement and Engagement, 2018, 4, 3.	2.9	6
254	Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?. Journal of Antimicrobial Chemotherapy, 2018, 73, 3212-3215.	3.0	6
255	Challenges in the bioanalysis of tetracyclines: Epimerisation and chelation with metals. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1134-1135, 121807.	2.3	6
256	Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective Study. Infectious Diseases and Therapy, 0, , .	4.0	6
257	Pharmacokinetics and metabolism of FCE 22101 following its administration as the oral pro-drag FCE 22891. Journal of Antimicrobial Chemotherapy, 1992, 29, 179-185.	3.0	5
258	An evaluation of three new immunoassays for determination of serum gentamicin concentrations. Journal of Antimicrobial Chemotherapy, 1994, 34, 747-754.	3.0	5
259	Microbiologically proven bacterial infections in AIDS. Postgraduate Medical Journal, 1997, 73, 565-570.	1.8	5
260	Screening for EMRSA-16 in healthcare workers. Journal of Hospital Infection, 1997, 37, 75-77.	2.9	5
261	Pharmacodynamics of Ceftazidime plus the Serine β-Lactamase Inhibitor AM-112 against Escherichia coli Containing TEM-1 and CTX-M-1 β-Lactamases. Antimicrobial Agents and Chemotherapy, 2004, 48, 4482-4484.	3.2	5
262	Determination of avilamycin A and B in pig faeces by solid phase extraction and reverse-phase HPLC assay. International Journal of Antimicrobial Agents, 2004, 24, 511-514.	2.5	5
263	A non-fatal case of hantavirus cardiopulmonary syndrome imported into the UK (ex Panama), July 2014. Journal of Clinical Virology, 2015, 67, 52-55.	3.1	5
264	Antibacterial effect of imipenem/relebactam on aerobic Gram-negative bacilli: in vitro simulations of 7 or 14 day human exposures. Journal of Antimicrobial Chemotherapy, 2019, 74, 1945-1951.	3.0	5
265	Comparative evaluation of eight in vitro pharmacodynamic models of infection: Activity of moxifloxacin against Escherichia coli and Streptococcus pneumoniae as an exemplary example. International Journal of Antimicrobial Agents, 2020, 55, 105809.	2.5	5
266	Clinical diagnosis and treatment of common respiratory tract infections in relation to microbiological profiles in rural health facilities in China: implications for antibiotic stewardship. BMC Family Practice, 2021, 22, 87.	2.9	5
267	Once-a-day carbapenem therapy. Journal of Antimicrobial Chemotherapy, 1996, 38, 327-328.	3.0	4
268	The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model. Clinical Microbiology and Infection, 1999, 5, 195-200.	6.0	4
269	Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in anin vitropharmacokinetic model of infection. Journal of Antimicrobial Chemotherapy, 2016, 71, 1270-1278.	3.0	4
270	Towards better antimicrobial susceptibility testing: impact of theJournal of Antimicrobial Chemotherapy. Journal of Antimicrobial Chemotherapy, 2017, 72, 323-329.	3.0	4

#	Article	IF	CITATIONS
271	Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection. Journal of Antimicrobial Chemotherapy, 2018, 73, 1305-1313.	3.0	4
272	1387. Phase I Study to Evaluate the Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Doses (SAD/MAD) of Intravenous (IV) Minocycline in Healthy Adult Subjects. Open Forum Infectious Diseases, 2018, 5, S425-S426.	0.9	4
273	Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection. International Journal of Antimicrobial Agents, 2019, 54, 626-632.	2.5	4
274	Comment on: Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study. Journal of Antimicrobial Chemotherapy, 2021, 76, 1949-1950.	3.0	4
275	False-positive agglutinations withListeria monocytogenes using a commercial kit for Lancefield grouping of beta-haemolytic streptococci. European Journal of Clinical Microbiology and Infectious Diseases, 1988, 7, 208-210.	2.9	3
276	Antimicrobial chemotherapy of meningitis due to Listeria monocytogenes in adults. Journal of Infection, 1992, 25, 119-120.	3.3	3
277	ANAEROBIC EXPERIENCE OF FLUOROQUINOLONES AND EPIDEMIOLOGY IN THE UNITED KINGDOM AND EUROPE. Infectious Diseases in Clinical Practice, 1996, 5, S85-S91.	0.3	3
278	Difficulties in the assay of liposomal amikacin (MiKasome) in serum. Journal of Antimicrobial Chemotherapy, 1999, 43, 719-721.	3.0	3
279	Choosing the right anticoagulant: a critical choice when assessing pharmacokinetic parameters for tetracyclines obtained from human blood samples. Journal of Antimicrobial Chemotherapy, 2019, 74, 3643-3645.	3.0	3
280	The pharmacodynamics of fosfomycin against Staphylococcus aureus studied in an in vitro model of infection. International Journal of Antimicrobial Agents, 2020, 56, 105985.	2.5	3
281	Risk factors for hospital readmission following complicated urinary tract infection. Scientific Reports, 2021, 11, 6926.	3.3	3
282	Risk factors for enterococcal urinary tract infections: a multinational, retrospective cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2005-2010.	2.9	3
283	The pharmacodynamics of minocycline alone and in combination with rifampicin against <i>Staphylococcus aureus</i> studied in an <i>in vitro</i> pharmacokinetic model of infection. Journal of Antimicrobial Chemotherapy, 2021, 76, 1840-1844.	3.0	3
284	In Vitro Activities of Y-688, a New 7-Substituted Fluoroquinolone, against Anaerobic Bacteria. Antimicrobial Agents and Chemotherapy, 1998, 42, 419-424.	3.2	3
285	Exploring the Pharmacokinetics of Phenoxymethylpenicillin (Penicillin-V) in Adults: A Healthy Volunteer Study. Open Forum Infectious Diseases, 2021, 8, ofab573.	0.9	3
286	The activity of ceflxime against 715 urinary isolates of Enterobacteriaceae isolated from general practice and out-patients in twenty centres across tbe British Isles. Journal of Antimicrobial Chemotherapy, 1992, 30, 554-556.	3.0	2
287	Decrease in antibiotic susceptibility or increase in resistance? defects of present antimicrobial susceptibility surveillance. Journal of Antimicrobial Chemotherapy, 1998, 42, 547-548.	3.0	2
288	Use of Intravenous Co-Trimoxazole to Treat Bacterial Infection: Analysis of 50 Treatment Episodes. Journal of Chemotherapy, 2010, 22, 267-269.	1.5	2

#	Article	IF	CITATIONS
289	Hydroxychloroquine serum concentrations in non-critical care patients infected with SARS-CoV-2. Journal of Global Antimicrobial Resistance, 2021, 24, 178-179.	2.2	2
290	Cost-effectiveness of rapid laboratory-based mass-spectrometry diagnosis of bloodstream infection: evidence from the RAPIDO randomised controlled trial. BMJ Open, 2021, 11, e044623.	1.9	2
291	When is pencillin monotherapy tbe antibiotic treatment of choice?. Journal of Antimicrobial Chemotherapy, 1992, 29, 239-243.	3.0	1
292	The management of mycobacterial infection— a UK survey. Journal of Antimicrobial Chemotherapy, 1995, 36, 745-747.	3.0	1
293	Control of varicella-zoster infection on renal and other specialist units. Journal of Hospital Infection, 1997, 36, 133-140.	2.9	1
294	A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. Journal of Antimicrobial Chemotherapy, 2001, 48, 161-161.	3.0	1
295	Antimicrobial therapy: principles of use. Medicine, 2013, 41, 635-641.	0.4	1
296	Comment on: Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections. Journal of Antimicrobial Chemotherapy, 2020, 75, 2711-2712.	3.0	1
297	Emulating the MERINO randomised control trial using data from an observational cohort and trial of rapid diagnostic (BSI-FOO). PLoS ONE, 2022, 17, e0268807.	2.5	1
298	Penetration of cefixime into the cerebrospinal fluid of patients with non-inflamed meninges. Journal of Antimicrobial Chemotherapy, 1993, 32, 783-784.	3.0	0
299	Trends in original research published from the United Kingdom in the antimicrobial chemotherapy literature, 1980–1994. Journal of Antimicrobial Chemotherapy, 1996, 38, 1097-1101.	3.0	0
300	In vitro methods for confirming reduced susceptibility to cefuroxime amongHaemophilus influenzae isolates. European Journal of Clinical Microbiology and Infectious Diseases, 1997, 16, 328-329.	2.9	0
301	Novel strategies for the use of antibiotics. Current Opinion in Infectious Diseases, 1998, 11, 471-474.	3.1	0
302	Antimicrobial Activity of Moxifloxacin and Levofloxacin Photodegradation Products. Drugs, 1999, 58, 144-145.	10.9	0
303	Clinafloxacin serum concentrations in a patient on continuous veno-venous haemofiltration. Journal of Antimicrobial Chemotherapy, 2000, 45, 927-928.	3.0	0
304	Trends in original research published from the United Kingdom in the antimicrobial literature. Journal of Antimicrobial Chemotherapy, 2002, 49, 429-430.	3.0	0
305	Tigecycline pharmacokinetic/pharmacodynamic update. Journal of Antimicrobial Chemotherapy, 2010, 65, 1549-1549.	3.0	0
306	Prospective observational cohort study of patients colonised and infected with Methicillin Resistant S.aureus (MRSA) in a UK teaching hospital. Journal of Infection, 2011, 63, e33.	3.3	0

#	Article	IF	CITATIONS
307	Reply to "Breakthrough Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae during Combination Therapy with Colistin and Tigecycline― Antimicrobial Agents and Chemotherapy, 2012, 56, 4996-4996.	3.2	0
308	Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07authors' response. Journal of Antimicrobial Chemotherapy, 2013, 68, 1693-1694.	3.0	0
309	Patient and public involvement in infection clinical research. Clinical Microbiology and Infection, 2018, 24, 1121-1122.	6.0	0
310	Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?—authors' response. Journal of Antimicrobial Chemotherapy, 2019, 74, 1767-1767.	3.0	0
311	Pharmacodynamics of aztreonam against Escherichia coli and Klebsiella oxytoca: defining pharmacodynamic targets. Journal of Antimicrobial Chemotherapy, 2020, 75, 772-773.	3.0	0
312	Impact of recent EUCAST method changes in an English region. Journal of Antimicrobial Chemotherapy, 2021, 76, 3066.	3.0	0
313	Pharmacokinetics of Lopinavir/Ritonavir in Hospitalized Patients with COVID-19 Not Requiring Critical Care. Microbial Drug Resistance, 2022, , .	2.0	0
314	Expected phenotypes and Expert Rules are Important Complements to Antimicrobial Susceptibility Testing. Clinical Microbiology and Infection, 2022, , .	6.0	0
315	Comment on: Vancomycin in adult prescribing: is it time to move on from trough-based dosing in the UK?. Journal of Antimicrobial Chemotherapy, 2022, , .	3.0	0